|Slideshows|November 22, 2016

AHA 2016: Cardiovascular Health and Cognition

Do lipid-lowering medications or low vitamin D levels in mid-life cause neurocognitive deficits? What effect does hypotension have on TBI outcomes?

Presentations at the American Heart Association Scientific Sessions examined the association of PCSK9 inhibitors and neurocognitive deficits, the effect of depth and dose of hypotension on mortality in traumatic brain injury, and a possible link between low vitamin D levels in mid-life and cognitive deficits 20 years later.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

AHA 2016: Cardiovascular Health and Cognition

Newsletter

Related Content

NeurologyLive® Brain Games: December 7, 2025

Epidiolex CBD Treatment Effective Across Range of Developmental Epileptic Encephalopathies

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy

Japanese Post Marketing Study Shows Long-Term Efficacy of Stiripentol in Dravet Syndrome

Latest CME

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease

Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic